tradmap

UNH Financials UnitedHealth Group

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 11.7% per year over the past 5 years.
  • Net income has grown slower than revenue (-4.8% vs 11.7% per year).
  • Operating margin has contracted, at 4.2% in the latest year.
  • Free cash flow has declined 4.4% per year over the past 5 years.

Financial health

  • Total debt ($77.7B) exceeds cash ($24.4B); net debt is $53.3B.
  • Total debt has grown in line with revenue (12.9% vs 11.7% per year).
  • Operating income covered interest expense 4.7× in the latest year, down from 13× 5 years ago.
  • Total debt is 3.3× EBITDA.

Shareholder returns

  • Dividends have been paid for 15 consecutive years, consuming 65.7% of earnings and 49.2% of free cash flow.
  • The dividend has grown 11.5% per year over the past 5 years.
Revenue & net income
$0 $224B $448B 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
0% 45% 90% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
$0 $13B $26B 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $39B $78B 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$28B $296M $29B $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 $447.6B $12.1B 88.7% 4.2% $16.1B $77.7B $24.4B
2024 $400.3B $14.4B 88.3% 8.1% $20.7B $76.2B $25.3B
2023 $371.6B $22.4B 89.6% 8.7% $25.7B $61.5B $25.4B
2022 $324.2B $20.1B 89.6% 8.8% $23.4B $56.8B $23.4B
2021 $287.6B $17.3B 89.2% 8.3% $19.9B $44.6B $21.4B
2020 $257.1B $15.4B 88.0% 8.7% $20.1B $42.3B $16.9B
2019 $242.2B $13.8B 88.4% 8.1% $16.4B $39.5B $11.0B
2018 $226.2B $12.0B 88.1% 7.7% $13.7B $35.2B $10.9B
2017 $201.2B $10.6B 88.0% 7.6% $11.6B $31.1B $12.0B
2016 $184.8B $7.0B 86.8% 7.0% $8.1B $32.8B $10.4B
2015 $157.1B $5.8B 0.0% 7.0% $8.2B $31.8B $10.9B
2014 $130.5B $5.6B 0.0% 7.9% $6.5B $17.3B $7.5B
2013 $122.5B $5.6B 0.0% 7.9% $5.7B $16.9B $7.3B
2012 $110.6B $5.5B 0.0% 8.4% $6.1B $16.8B $8.4B
2011 $101.9B $5.1B 0.0% 8.3% $5.9B $11.6B $9.4B

Valuation over time

How the market has priced UNH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 17.1 34.2 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/E
Price / sales (P/S)
0.0 0.8 1.5 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/S
Dividend yield (%)
0.0 1.7 3.3 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
Dividend yield %

Frequently asked questions

Is UNH growing its revenue and profit?

Over the past 5 years, UnitedHealth Group's revenue has grown 11.7% per year, and net income declined 4.8% per year. These are computed facts, not advice.

How much debt does UNH have?

As of FY2025, UnitedHealth Group reported $77.7B of total debt against $24.4B of cash; operating income covered interest expense 4.7×.

What is UNH's profit margin?

In FY2025, gross margin was 88.7%, operating margin 4.2%, and net margin 2.7%.

What is UNH's P/E ratio?

As of Jun '26, UnitedHealth Group traded at a price-to-earnings ratio of about 31.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.